anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In most physiological situations, the adequate amount of protein necessary to promote health is more and more well known. However, for an adequate protein intake, it was shown that the kinetic of amino acid delivery to the organism has an influence on the efficiency of protein utilization. In particular, caseins, slowly digested milk proteins, promote a better protein balance than rapidly digested milk soluble proteins in young subjects (Boirie et al., 1997). In addition, changing protein feeding pattern (80% of daily protein consumed at noon vs 25%) significantly affect protein balance (Arnal et al., 2000). In young healthy individuals, the best protein efficiency is obtained by spreading protein absorption over time (casein, and/or 4 isoproteic meal per day). On the contrary, in older individuals, due to alteration in the sensitivity of protein metabolism to feeding, it is better to use rapidly digested proteins (Dangin et al., 2003), and / or to have a protein-rich meal once a day (Arnal et al., 1999).

Another physiological situation that was not studied in this regard is obesity. Obesity incidence is rapidly increasing around the world. When body mass index (weight / height2) becomes too high (\>30), it is often suggested to restrict energy intake. However, severe energy restriction leads to fat mass loss, but also to lean body mass loss, which should be prevented. Our aim is to test whether for an adequate amount of total protein, it is possible to preserve lean body mass by using either casein, or milk soluble proteins, or by changing protein feeding pattern.
Subjects with baseline BCVA from 20/60 to 20/16000. The first five (5) to receive 2.0 μM concentration intravitreal at each Day 0 and Day 21, the subsequent five (5) to receive 0.2 μM intravitreal injection at each Day 0 and Day 21, additional subjects (up to ten \[10\]) to receive one of the dosing options (either 2.0 μM or 0.2 μM) at each Day 0 and Day 21, at the discretion of the Investigator and Sponsor.
Delayed graft function (DGF) is a frequently observed complication following kidney transplantation (KT). Our prior research revealed dynamic shifts in salivary microbiota post-KT with immediate graft function (IGF), yet its behavior during DGF remains unexplored. Five recipients with DGF and 35 recipients with IGF were enrolled. Saliva samples were collected during the perioperative period, and 16S rRNA gene sequencing was performed. The salivary microbiota of IGFs changed significantly and gradually stabilized with the recovery of renal function. The salivary microbiota composition of DGFs was significantly different from that of IGFs, although the trend of variation appeared to be similar to that of IGFs. Salivary microbiota that differed significantly between patients with DGF and IGF at 1 day after transplantation were able to accurately distinguish the two groups in the randomForest algorithm (accuracy = 0.8333, sensitivity = 0.7778, specificity = 1, and area under curve = 0.85), with Selenomonas playing an important role. Bacteroidales (Spearman's r =  - 0.4872 and p = 0.0293) and Veillonella (Spearmen's r =  - 0.5474 and p = 0.0125) were significantly associated with the serum creatinine in DGF patients. Moreover, the significant differences in overall salivary microbiota structure between DGF and IGF patients disappeared upon long-term follow-up. This is the first study to investigate the dynamic changes in salivary microbiota in DGFs. Our findings suggested that salivary microbiota was able to predict DGF in the early stages after kidney transplantation, which might help the perioperative clinical management and early-stage intervention of kidney transplant recipients. KEY POINTS: • Salivary microbiota on the first day after KT could predict DGF. • Alterations in salivary taxa after KT are related to recovery of renal function.
FIELD: medicine, ophthalmology, pharmacy. SUBSTANCE: ophthalmic drops have diclofenac as an active agent and stabilizing agent of biological, physico-chemical properties and/or resistance to bacterial contamination as accessory substance and buffer mixture. Ophthalmic drops have additionally dimedrol as an active agent, polyvinylpyrrolidone or polyvinyl alcohol as stabilizing agent and methylcellulose derivative (carboxymethylcellulose sodium) and chlorhexidine also. Ophthalmic drops have additionally antioxidant, antagonists of H1-receptors, quifenadine or sequifenadine, antiallergic drugs and stabilizing agents of cellular functions: theophylline or cromoglicate sodium or nedocromil sodium. Agent has no toxicity, apyretic, it does not show topical irritant effect, retains antiviral activity completely. EFFECT: enhanced effectiveness of ophthalmic drops. 11 cl, 6 ex
Methods, systems, and computer-readable storage mediums for standardizing node field-value pairs of node profiles generated using electronic activities across multiple entities are described. In one aspect, the system can access, for a node profile of an entity, data points linked to the node profile. The system may determine a seniority value and a department value using the data points. The system may generate a normalized job title value by combining the seniority value and the department value using a title formatting policy specifying a format in which to combine to the seniority value and the department value. The normalized job title value may identify the seniority and department of entity. The system may store an association between the node profile and the normalized job title value in one or more data structures.
Method 700 may include obtaining 702, at server 110, a user input from a user interface. The user input may define interval 212 for a desired CPR certification schedule. Method 700 may include generating 704, at server 110, CPR certification program 200. Generating 704 CPR certification program 200 may include generating at least two task groups 222. Each task group 222 of the at least two task groups 222 may include a healthcare certification task 228. Method 700 may include administering, at server 110, CPR certification program 200. Administering CPR certification program 200 may include assigning 706, at interval 212 defined by the user input, one task group 222 of the at least two task groups 222 to a user enrolled in CPR certification program 200, and receiving 708 an indication that the enrolled user has completed healthcare certification task 228 of the assigned one task group 222.
Fractional Curettage is the most widely used for diagnostic and treatment abnormal uterine bleeding. The patient categorize post-operative pain as mild to moderate. Therefore, the effective analgesic added on intraoperative and post-operative is the most important factor in patient's satisfaction, patient well co-operation, shortness time of operation, decrease unpleasant symptoms and rapid recovery. However, there are many anesthetic technique that can be used to relive pain in the operation such as local anesthesia, total intravenous anesthesia, regional anesthesia or oral analgesic drugs.

Intravenous Fentanyl is an short acting opioid. It has a fast onset of action within 2 minutes and short duration of action 30-60 minutes. Respiratory depression, hypotension and bradycardia are adverse effects that might delayed discharge especially in one day surgery e.g. fractional curettage. Etoricoxib is an oral COX-2 specific inhibitor which can be used to relieve the pain. The onset of analgesia can be occurred within 24 minutes which peak plasma level within 60 minutes. There are many empirical evidences to support the results of post-operative pain after used oral Etoricoxib or intravenous Fentanyl. However, there are less evidences to support efficiency of oral Etoricoxib versus intravenous Fentanyl on post-operative Pain in fractional curettage under TIVA
ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously in 14-day cycles, 4 mg/kg IV cycle 1, day 2 followed by 2 mg/kg IV cycle 1, day 8, 4mg/kg IV cycle 1, day 15, and then one dose of 4 mg/kg every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on day 1 and 15 of a 28-day cycle.
PURPOSE OF REVIEW: Physical pain is an underrecognized area of dysregulation among those with borderline personality disorder (BPD). Disturbances are observed within the experience of acute, chronic, and everyday physical pain experiences for people with BPD. We aimed to synthesize research findings on multiple areas of dysregulation in BPD in order to highlight potential mechanisms underlying the association between BPD and physical pain dysregulation.
RECENT FINDINGS: Potential biological mechanisms include altered neural responses to painful stimuli within cognitive-affective regions of the brain, as well as potentially low basal levels of endogenous opioids. Emotion dysregulation broadly mediates dysregulation of physical pain. Certain psychological experiences may attenuate acute physical pain, such as dissociation, whereas others, such as negative affect, may exacerbate it. Social challenges between patients with BPD and healthcare providers may hinder appropriate treatment of chronic pain. Dysregulated physical pain is common in BPD and important in shaping health outcomes including elevated BPD symptoms, chronic pain conditions, and risk for problematic substance use.
Patients were premedicated with 0.05 mg kg-1 of midazolam (PanPharma), 5 minutes before the starting of the procedure. Afterwards, sedation induction was performed with 1 mcg kg-1 of fentanyl (Panpharma; SanMed) and 0.5 mg kg-1 of propofol (Fresenius Kabi; Amicus Pharma).
This randomized controlled trial will enroll patients with vestibular migraine from the First Affiliated Hospital of Jiaxing University. All participants will be randomly assigned to two groups. Participants will receive acupuncture in the treatment group, while participants in the control group will be treated by venlafaxine. All treatments will be given for 8 weeks. The primary outcome measures are change in vertigo/migraine days and vertigo/migraine attacks, vertigo severity, and migraine intensity per 4 weeks from baseline. The secondary outcome measures are change in dosage of rescue medication, anxiety level，depression level，and quality of life per 4 weeks from baseline.
Orally administrable pharmaceutical compositions for binding bile-acids in the gastro-intestinal tract and having blood cholesterol lowering activity comprise a carrier and a synthetic, non-toxic polymer having a skeleton inert to digestive enzymes and a molecular weight in excess of about 3000 and containing ionizable amino groups, the polymer if water-insoluble having the property of binding at least 30% by weight of the available glycocholic acid into a form incapable of dialysis through a cellulose membrane within 5 minutes when exposed to an equal weight of the acid, and having a moisture content of at least 65% after equilibration with air at 100% humidity at 25 DEG  C., and, if water-soluble, having an equivalent weight, based on the ionizable amino groups of at least 500 and the property of binding at least 80% of its weight of glycocholic acid in vitro into a form incapable of dialysis through a cellulose membrane. Suitable polymers are divinyl benzene cross-linked polystyrene quaternary ammonium salt resins, e.g. those sold under the Trade Mark "Dowex 1," linear acrylic type quaternary ammonium salt polymers having a molecular weight of the order of 2,000,000, e.g. those sold under the Trade Marks "Acryloid CQ," and "Acrysol CQ," and its tertiary amine salt "Acrysol CA," polyethyleneimine having an average molecular weight of about 30,000 and a co-polymer of acrylamide and vinyl benzene trimethylammonium chloride in a weight ratio of about 30 : 70 having an equivalent weight of about 302 and an average molecular weight of above 100,000.  The compositions may be in conventional forms, e.g. a tablet, elixir, syrup or flavoured aqueous solution.
This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
Herlyn-Werner-Wunderlich (HWW) syndrome is characterized by obstructed hemivagina and ipsilateral renal anomaly, a rare congenital anomaly of the genitourinary tract, resulting from malformations of the renal tract associated with Müllerian duct anomalies. The initial symptoms of HWW frequently present after menarche and may be nonspecific, leading to a delayed diagnosis. We presented a 19-year-old female with 3-year hematuria and abdominal pain. The final diagnosis of HWW syndrome with a rare vesicovaginal fistula was made. The treatment of HWW syndrome typically involves surgical intervention. The primary treatment is resection or removal of the obstructed vaginal septum. The patient underwent excision of vaginal septum and vaginal reconstruction via hysteroscopy, as well as repair of the vesicovaginal fistula. The patient improved well after surgery and fully recovered without sequelae after 3 months. In addition, unilateral renal agenesis is one of congenital abnormalities of the kidney and urinary tract, which are the most frequent cause of chronic kidney disease (CKD) in children. This report describes a patient of HWW syndrome with rarely combined vesicovaginal fistula, and highlights the importance of early recognition and management to prevent associated complications.
Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
In a randomized, double-blind, placebo-controlled trial in HIV-1-infected women and their neonates conducted to determine the utility of zidovudine for the prevention of maternal-fetal HIV-1 transmission, zidovudine syrup at 2 mg/kg was administered every 6 hours for 6 weeks to neonates beginning within 12 hours following birth. The most commonly reported adverse reactions were anemia (hemoglobin < 9 g/dL) and neutropenia (< 1,000 cells/mm3). Anemia occurred in 22% of the neonates who received zidovudine and in 12% of the neonates who received placebo. The mean difference in hemoglobin values was less than 1 g/dL for neonates receiving zidovudine compared with neonates receiving placebo. No neonates with anemia required transfusion and all hemoglobin values spontaneously returned to normal within 6 weeks after completion of therapy with zidovudine. Neutropenia in neonates was reported with similar frequency in the group that received zidovudine (21%) and in the group that received placebo (27%). The long-term consequences of in utero and infant exposure to zidovudine are unknown.
Some patients with paroxysmal and/or chronic atrial fibrillation or atrial flutter and a coexisting accessory AV pathway have developed increased antegrade conduction across the accessory pathway bypassing the AV node, producing a very rapid ventricular response or ventricular fibrillation after receiving intravenous verapamil (or digitalis). Although a risk of this occurring with oral verapamil has not been established, such patients receiving oral verapamil may be at risk and its use in these patients is contraindicated ( see CONTRAINDICATIONS). Treatment is usually DC-cardioversion. Cardioversion has been used safely and effectively after oral verapamil hydrochloride. 

Atrioventricular block: The effect of verapamil on AV conduction and the SA node may cause asymptomatic first-degree AV block and transient bradycardia, sometimes accompanied by nodal escape rhythms. PR-interval prolongation is correlated with verapamil plasma concentrations especially during the early titration phase of therapy. Higher degrees of AV block, however, were infrequently (0.8%) observed. Marked first-degree block or progressive development to second-or third-degree AV block requires a reduction in dosage or, in rare instances, discontinuation of verapamil HCl and institution of appropriate therapy, depending on the clinical situation. 

Patients with hypertrophic cardiomyopathy (IHSS): In 120 patients with hypertrophic cardiomyopathy (most of them refractory or intolerant to propranolol) who received therapy with verapamil at doses up to 720 mg/day, a variety of serious adverse effects were seen. Three patients died in pulmonary edema; all had severe left ventricular outflow obstruction and a past history of left ventricular dysfunction. Eight other patients had pulmonary edema and/or severe hypotension; abnormally high (greater than 20 mm Hg) pulmonary wedge pressure and a marked left ventricular outflow obstruction were present in most of these patients. Concomitant administration of quinidine (see PRECAUTIONS, Drug interactions) preceded the severe hypotension in 3 of the 8 patients (2 of whom developed pulmonary edema). Sinus bradycardia occurred in 11% of the patients, second-degree AV block in 4%, and sinus arrest in 2%. It must be appreciated that this group of patients had a serious disease with a high mortality rate. Most adverse effects responded well to dose reduction, and only rarely did verapamil use have to be discontinued.
PURPOSE:To obtain a highly safe MB-530B derivative having inhibitory action on sterol synthesis, by converting a carboxylic acid having a specific structure, a pharmacologically acceptable salt, ester or ring closed lactone derivative thereof. CONSTITUTION:An MB-530B derivative is converted into a carboxylic acid having formula I , a pharmacologically acceptable salt, ester or ring closed lactone derivative thereof. In the formula I , R<1> represents formula II or III, and R<2> represents 1-10C alkyl group except S-butyl group. The MB-530B derivative is obtained by bringing a carboxylic acid having formula IV, a pharmacologically acceptable salt, ester or a ring closed lactone derivative thereof into contact with a converting microorganism capable of hydroxylating the carbon atom at the 3- or 6-position of the carboxylic acid, etc. or a cell-free extract thereof to hydroxylate enzymically the carboxylic acid of formula IV, etc., and subjecting the resultant conversion product to the hydrolyzing, salt forming, esterifying and lactone forming reactions. R<2> in formula IV is the same as R<2> in formula I .
The invention provides an application of Rheum tanguticum Maxim petioles in preparing health food or medicine. In particular to the application of the rhubarb tang tangut leaves and stems in preparing antioxidant health food and the application of the rhubarb tang tangut leaves and stems in preparing antioxidant, uric acid reducing, heat clearing and detoxifying drugs. The study of the invention finds that the Rheum tanguticum Maxim petiole has good effects of resisting oxidation, reducing uric acid, clearing heat and removing toxicity, and can prevent and/or treat gout or diminish inflammation. Therefore, the rhubarb petiole of tangut can be prepared into health food or medicine with related efficacy. The invention also provides a preparation method of the rhubarb tang juice, which can overcome the astringent taste of the tang of rhubarb and obtain the rhubarb tang juice with excellent taste. The invention develops the economic value of the Rheum tanguticum Maxim petiole and has good market prospect.
NEW MATERIAL:The compound of formula I (R<1> is lower alkyl, lower alkoxy- substituted lower alkyl, etc.; R<2> is H or halogen; R<3> is H or lower alkyl) and its salt. EXAMPLE:4,5-Dichloro-6-(1-methyl-5-pyrazolylcarbonyl)-1,3-benzodioxole-2- carboxylic acid. USE:A diuretic useful for the remedy and prevention of congestive heart, various edemata, etc. PREPARATION:The objective compound of formula I can be produced either by reacting a 1,2-benzenediol compound of formula II with an acetic acid compound of formula III (Y is reactive residue) or by oxidizing a benzodioxole compound of formula IV. The preferable daily dose of the compound of formula I is usually 0.1-200mg/kg, especially 0.3-100mg/kg.
PURPOSE OF REVIEW: Percutaneous radiofrequency (RF) catheter ablation is an established strategy to prevent ventricular tachycardia (VT) recurrence and ICD shocks. Yet delivery of durable lesion sets by means of traditional unipolar radiofrequency ablation remains challenging, and left ventricular transmurality is rarely achieved. Failure to ablate and eliminate functionally relevant areas is particularly common in deep intramyocardial substrates, e.g. septal VT and cardiomyopathies. Here, we aim to give a practical-orientated overview of advanced and emerging RF ablation technologies to target these complex VT substrates. We summarize recent evidence in support of these technologies and share experiences from a tertiary VT centre to highlight important "hands-on" considerations for operators new to advanced RF ablation strategies.
RECENT FINDINGS: A number of innovative and modified radiofrequency ablation approaches have been proposed to increase energy delivery to the myocardium and maximize RF lesion dimensions and depth. These include measures of impedance modulation, combinations of simultaneous unipolar ablations or true bipolar ablation, intramyocardial RF delivery via wires or extendable RF needles and investigational linear or spherical catheter designs. Recent new clinical evidence for the efficacy and safety of these investigational technologies and strategies merits a re-evaluation of their role and clinic application for percutaneous VT ablations. Complexity of substrates targeted with percutaneous VT ablation is increasing and requires detailed preprocedural imaging to characterize the substrate to inform the procedural approach and selection of ablation technology. Depending on local experience, options for additional and/or complementary interventional treatments should be considered upfront in challenging substrates to improve the success rates of index procedures. Advanced RF technologies available for clinical VT ablations include impedance modulation via hypotonic irrigation or additional dispersive patches and simultaneous unipolar as well as true bipolar ablation. Promising investigational RF technologies involve an extendable needle RF catheter, intramyocardial RF delivery over intentionally perforated wires as well as a variety of innovative ablation catheter designs including multipolar linear, spherical and partially insulated ablation catheters.
Treatment group will receive chair-based exercise training. Chair-based exercise training consisting of 20 different exercises will be applied in 2-3 sets with an average of 8-15 repetitions. Rest between sets will average 45-60 seconds.
The material was mixed using a plastic spatula on a mixing pad or glass with a powder-to-liquid ratio of 1:1 until it reached a homogeneous consistency, which took approximately 45 -60 seconds. Then the material was applied to the cavity and allowed to set for its self-curing time of 4 and a half minutes.